CLONORGAN

Established in 2018 and based in Chengdu, China, CLONORGAN is a biological company that focuses on developing organ and tissue therapy techniques. The founder, Dengke Pan, is deputy Leader of the Xenotransplantation Group of the Organ Transplantation Society of the Chinese Medical Association. More than 22% of members of the research team have master's degrees. The company has been honored as a technology-based SME by the Ministry of Science and Technology, a Chinese-funded enterprise in Chengdu, and an Eagle Enterprise in Chengdu Hi-Tech Zone in 2019.

In September 2025, CLONORGAN closed a Series A++ co-led by new investors Beijia Investment Management and Lightspeed China Partnersand, new investors ChipBio, CUFE Rising Capital Management, YuanBio Venture, with participation from other investors. The company provides biological products for xenogeneic organs and biomedical tissues, which adopt gene editing and cloning technology. It specializes in fund editing and cloning services, tissue organ transplantation trials such as liver, pancreatic islets, and kidneys, and clinical research. The product includes xenogeneic organ donor pigs, medical bio-donor pigs, and low immunogenicity biomaterials.

The company generates revenue by providing gene editing and cloning services, experimental simulation of pigs, gene-edited human disease model pigs, etc.